Inhibitor Therapeutics, Inc. (INTI)

Inhibitor Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-3.31	-3.3	-3.34	-3.03	12.11	-0.3
Stock-Based Compensation	0.03	0.02	0.04	0.01	-	0.04
Other Operating Activities	0	0	-	-	-0.51	-0.04
Change in Accounts Payable	0.03	0.03	0.04	0.4	0.14	0.05
Change in Other Net Operating Assets	0.02	0.02	0.02	-0.09	0	0.03
Operating Cash Flow	-3.22	-3.23	-3.23	-2.7	11.74	-0.22
Operating Cash Flow Growth	-	-	-	-	-	-
Long-Term Debt Issued	-	-	-	-	0.18	0.18
Long-Term Debt Repaid	-	-	-	-0.41	-	-
Net Debt Issued (Repaid)	-	-	-	-0.41	0.18	0.18
Financing Cash Flow	-	-	-	-0.41	0.18	0.18
Net Cash Flow	-3.22	-3.23	-3.23	-3.11	11.92	-0.04
Levered Free Cash Flow	-2.03	-2.07	-2.18	-1.8	-0.6	-0.12
Unlevered Free Cash Flow	-2.03	-2.07	-2.18	-1.8	-0.59	-0.11
Change in Working Capital	0.05	0.04	0.07	0.31	0.14	0.08

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 18, 2026

Data Sources Report a data error